Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Bjørn Ostenstad"'
Autor:
Elisa Jacobsen Pulczynski, Mikkel Runason Simonsen, Outi Kuittinen, Unn-Merete Fagerli, Martin Erlanson, Øystein Fluge, Sirpa Leppä, Bjørn Østenstad, Alexander Fosså, Mikael Eriksson, Tarec El-Galaly, Hanne Kuitunen, Karin Papworth, Maria Ljungqvist, Martin B. Pedersen, Marjukka Pollari
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/b356f734dc304e7dbf40d10412436a97
Autor:
Chloé B. Steen, Ellen Leich, June H. Myklebust, Sandra Lockmer, Jillian F. Wise, Björn E. Wahlin, Bjørn Østenstad, Knut Liestøl, Eva Kimby, Andreas Rosenwald, Erlend B. Smeland, Harald Holte, Ole Christian Lingjærde, Marianne Brodtkorb
Publikováno v:
Haematologica, Vol 104, Iss 10 (2019)
Externí odkaz:
https://doaj.org/article/14f9bc8f28ea4b32997d11ae47c2bc0b
Autor:
Elisa J. Pulczynski, Outi Kuittinen, Martin Erlanson, Hans Hagberg, Alexander Fosså, Mikael Eriksson, Marie Nordstrøm, Bjørn Østenstad, Øystein Fluge, Sirpa Leppä, Bente Fiirgaard, Hanne Bersvendsen, Unn-Merete Fagerli
Publikováno v:
Haematologica, Vol 100, Iss 4 (2015)
The Nordic Lymphoma Group has conducted a phase ll trial in newly diagnosed primary central nervous system lymphoma patients applying an age-adjusted multi-agent immunochemotherapy regimen, which in elderly patients included temozolomide maintenance
Externí odkaz:
https://doaj.org/article/cfd2ea922aca452f9ec762eb347634cc
Autor:
Ranjan Chrisanthar, Stian Knappskog, Erik Løkkevik, Gun Anker, Bjørn Ostenstad, Steinar Lundgren, Terje Risberg, Ingvil Mjaaland, Gudbrand Skjønsberg, Turid Aas, Ellen Schlichting, Hans E Fjösne, Arne Nysted, Johan Richard Lillehaug, Per Eystein Lønning
Publikováno v:
PLoS ONE, Vol 6, Iss 4, p e19249 (2011)
TP53 mutations have been associated with resistance to anthracyclines but not to taxanes in breast cancer patients. The MDM2 promoter single nucleotide polymorphism (SNP) T309G increases MDM2 activity and may reduce wild-type p53 protein activity. He
Externí odkaz:
https://doaj.org/article/4bfaa36fda054125abf21579ddb58681
Autor:
Ranjan Chrisanthar, Stian Knappskog, Erik Løkkevik, Gun Anker, Bjørn Østenstad, Steinar Lundgren, Elisabet O Berge, Terje Risberg, Ingvil Mjaaland, Lovise Maehle, Lars Fredrik Engebretsen, Johan Richard Lillehaug, Per Eystein Lønning
Publikováno v:
PLoS ONE, Vol 3, Iss 8, p e3062 (2008)
BACKGROUND: Chemoresistance is the main obstacle to cure in most malignant diseases. Anthracyclines are among the main drugs used for breast cancer therapy and in many other malignant conditions. Single parameter analysis or global gene expression pr
Externí odkaz:
https://doaj.org/article/a6d3e770a2f64f5abbff0257fde5c1e6